UK Domestic Plasma Fractionation Service

Concepts

• immunoglobulins
• leeds
• uk domestic plasma fractionation service
• toll fractionation service
• plasma fractionation market
• uk plasma
• uk’s initial step
• uk plasma.the uk
• fractionation services
• respective blood services

Location

Leeds

Description

NHS England and NHS Improvement (NHSEI) is undertaking a competitive dialogue process to select a single organisation to provide a toll fractionation service using UK Plasma. Please see below/ procurement documents for full details.

Total Quantity or Scope

NHS England and NHS Improvement (NHSE&I) in conjunction with NHS Blood and Transplant (NHSBT) issued Prior Information Notices (PIN) in August 2021 and January 2022, seeking to gather information and feedback from the plasma fractionation market, as recognised experts, to help inform the strategy to contract for fractionation services using UK plasma. Having reflected upon the feedback received, NHSE&I is now commencing a Competitive Dialogue process, to select a single organisation to provide a toll fractionation service using UK plasma.The UK recognises that medicinal products derived from UK plasma have not been manufactured for more than 20 years. As such there is a much to learn and/or relearn. This procurement, and the wider project its supports, are therefore seen as the UK’s initial step (or pilot project) to achieve partial self-sufficiency for plasma derived medicinal products for the exclusive use of NHS patients in the UK.As such, this procurement is not expected to be a one off exercise. Rather the learning from this project is expected to inform future procurements and how the UK works with selected fractionators to achieve its long term ambitions for self-sufficiency.As regards Northern Ireland, Scotland and Wales, the respective Blood Services (represented by their hosting bodies where applicable) for each of the regions have expressed interest in this procurement. Therefore the Blood Services for each region (including their hosting bodies where applicable), the Devolved Administration for each region and the NHS providers in each region (as potential buyers of products derived from fractionation) are included by NHSE&I as Participating Authorities ("PAs") within this Contract Notice, as further defined in the tender documents. This provides an option for each of the above bodies to be a party to the contractual arrangements that will result from this procurement (by entering into essentially identical but separate contracts, under the law and jurisdiction of the relevant region in each case), but does not bind them to do so. Further details of the decision and implementation processes for the PAs in Northern Ireland, Scotland and Wales will be provided during the next stage of this procurement (Invitation to Participate in Dialogue The Authority and PA’s reserve the right to amend any plasma volumes stated within the procurement documents.Interested organisations can register their interest and access the procurement documents for full details here https://health-family.force.com/s/WelcomeOnce registered, you will be invited to sign a tripartite non-disclosure agreement (NDA). If you have previously signed an NDA as part of the 2 PIN notices issued for this tender, the NDA continues to apply during the tender period and until a contract has been entered into.The deadline for completion of the Selection Questionnaire within Atamis is 12th May 2022 at 13:00hrs

CPV Codes

• 33651520 - Immunoglobulins

Indicators

• Bids should cover the whole contract.
• Renewals are not available.
• Performance considerations apply.
• Professional qualifications are sought.
• Award on basis of price and quality.

Other Information

Please see procurement documents for full details